Q-omics provides the consensus-scored MGAT5B profile across patient tissues and cancer cell-line models. MGAT5B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MGAT5B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MGAT5B RNA expression shows 17,162 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where MGAT5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT5B survival associations across molecular data types. MGAT5B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT5B RNA expression–survival associations across cancer types. High MGAT5B expression shows unfavorable associations in KIRP, ACC, MESO, UVM, SKCM and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MGAT5B RNA expression.
This table summarizes MGAT5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MGAT5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT5B shows lower tumor expression in THCA, COAD and KICH and higher tumor expression in HNSC, BRCA and PRAD. The HNSC box plot shows higher MGAT5B RNA expression in tumor versus normal tissue (log2 FC = +0.777, t-test p < 0.001).
This table shows molecular features associated with MGAT5B in patient tissues and cancer cell lines. In patient samples, MGAT5B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
